RecruitingPhase 1Phase 2NCT07311746
Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia
Sponsor
M.D. Anderson Cancer Center
Enrollment
36 participants
Start Date
Apr 28, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
The goal of this clinical research study is to learn if the combination of ruxolitinib with cladribine and venetoclax can help to control the disease in patients with R/R T-PLL.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called Cladribine, a drug called Ruxolitinib, and others for people with refractory t-cell prolymphocytic leukemia and t-cell prolymphocytic leukemia. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGRuxolitinib
Given orally
DRUGCladribine
Given by injection
DRUGVenetoclax
Taken by mouth
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07311746
Related Trials
Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
NCT068107781 location
A Registry for People With T-cell Lymphoma
NCT0597814126 locations
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
NCT047715728 locations
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
NCT073562451 location
A Study of Ruxolitinib and Duvelisib in People With Lymphoma
NCT050100059 locations